selected miRNAs
cases of TNBC
TNBC patients
prognostic miRNAs
clinical validation
field of miRNA
Validation Study
selection of miRNAs
triple-negative breast cancer Multiplicom
validated multiplex miRNA test kit
use of miRNA diagnosis
suitable quantitative multiplex miRNA analysis
selected multiplex quantification method
prognosis of triple
available data Multiplicom
new cases
Validation of diagnostic
relevant intellectual property
new hires
marketing study
internal expertise
thorough analysis
best treatment
business plan
support of top-notch clinical scientists
annual peak sales
ISO
commercializing novel
multiplexed diagnostics
licensors
center
licensing negotiations
company
KOLs
substantial scientific evidence
track record
Euro pharmaceutical opportunity
expansion
departments
European-wide
excess
target patient population
IVD
consultants
following parts
competitive strategy
gross margin